TRCT
NTGN

Tower Research Capital (TRC)’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Tower Research Capital (TRC)’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,515
Closed -$3K – 4403
2019
Q4 		$3K Sell
2,515
-11,856
-82% -$18.9K ﹤0.01% 3004
2019
Q3 		$25K Buy
+14,371
New +$43.7K ﹤0.01% 2326
2018
Q4 		– Sell
-3,907
Closed -$33K – 4644
2018
Q3 		$33K Buy
+3,907
New +$43.3K ﹤0.01% 2024

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Athanor Capital New York $24.6M AUM 2.49% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tower Research Capital (TRC)'s NTGN Position: Q1 2020 in Review

Tower Research Capital (TRC) sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q1 2020, closing a stake of 2,515 shares — an estimated $3K sold.

Tower Research Capital (TRC) first reported a position in NTGN in Q3 2018 and held it in 3 quarters. The position peaked at $33K in Q3 2018. 43 funds tracked by Wall St. Rank hold NTGN as of Q1 2020.

  • Tower Research Capital (TRC) reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,515 Neon Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $3K.
  • Tower Research Capital (TRC) first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2018 and held it in 3 quarters.
  • Tower Research Capital (TRC)'s Neon Therapeutics, Inc. Common Stock position peaked at $33K in Q3 2018.
  • 43 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2020, filed 15 May 2020.